Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 959 of 6351
-
New trial tests smarter radiation to protect memory in lung cancer patients
Disease control Recruiting nowThis phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic …
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Smart drug targets breast cancer in the brain
Disease control OngoingThis phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitec…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody shows promise in shrinking MS brain lesions
Disease control OngoingPrimary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: * To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures * To evaluate the safety and tolerability…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New dosing schedule of immunotherapy shows promise for hard-to-treat lymphomas
Disease control CompletedThe primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Moderna's zika vaccine shows promise in Mid-Stage trial
Vaccine CompletedThis clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive…
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 07:51 UTC
-
New drug shows promise for reversing liver damage in NASH patients
Disease control CompletedThis is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
Phase 2 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo therapy shows promise for tough bone cancer
Disease control OngoingA phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Phase 2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for tough hodgkin lymphoma: immune drugs tested alone or together
Disease control OngoingThis study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: * Ipilimumab * Nivolumab
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug shows promise
Disease control OngoingThis study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Surgery gives new hope for hand movement after paralysis
Disease control Recruiting nowThe goal of this prospective, open-label cohort study is to assess functional outcomes in individuals with cervical spinal cord injury who have undergone nerve transfer surgery to restore upper limb function. The main questions it aims to answer are: * Does nerve transfer improv…
Sponsor: University of British Columbia • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New schizophrenia drug KarXT shows promise in Long-Term safety trial
Disease control CompletedThis is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in de novo subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia. In this OL study, all subjects will rec…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 26, 2026 18:11 UTC
-
New drug combo aims to deepen remission in myeloma transplant patients
Disease control OngoingThis is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autolog…
Phase 2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo shows promise for aggressive breast cancer
Disease control CompletedThis is a multicenter, randomized, 2 arm, open label, phase II study. It is designed to compare the efficacy and safety of abemaciclib combined with ET (letrozole or fulvestrant) versus a short course with induction chemotherapy with paclitaxel followed by maintenance therapy wit…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Mobile clinic brings one-stop HIV and addiction care to those who inject drugs
Disease control CompletedThe purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (MOUD) and medication for HIV treatment and prevention - to people who …
Sponsor: HIV Prevention Trials Network • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Zapping the heart with radiation to stop deadly rhythms
Disease control Recruiting nowVentricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical "short circuit" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. Current treatment for VT consists of either implanta…
Sponsor: John Sapp • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can we wake and kill sleeping breast cancer cells? new trial aims to find out
Disease control Recruiting nowThis clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard…
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Heart monitoring during lung cancer therapy may save lives
Disease control Recruiting nowThis is a prospective, randomized, controlled, multi-center phase III clinical trial that intends to evaluate the role of early cardiovascular intervention based on impedance cardiography in patients with locally advanced non-small cell lung cancer receiving radical radiochemothe…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo targets Tough-to-Treat cancers
Disease control OngoingBackground: Small cell lung cancer (SCLC) and high-grade neuroendocrine cancers (HGNEC) are aggressive neuroendocrine cancers. At first, SCLC and HGNEC respond to chemotherapy. But then they relapse quickly and become resistant to treatment. Researchers want to see if a combinat…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a magnetic helmet ease bladder pain? new study investigates
Symptom relief OngoingInterstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a common, chronic, and debilitating condition in women. Preliminary evidence suggests that IC/BPS pain can be reduced applying non-invasive repetitive transcranial magnetic stimulation (rTMS) to areas of the brain that regul…
Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can hidden heart rhythms explain dialysis risks?
Knowledge-focused CompletedThe study will examine the presence of cardiac arrhythmias in patients receiving hemodialysis and the role of diabetes, hypoglycemia and parameters related to uremia and the dialysis procedure. The study is designed as a prospective cohort study with 18 months follow-up. 70 pati…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC